Pharmathen S.A.   Report issue

For profit Phase 2
Founded: Athens Greece (1969)

Organization Overview

First Clinical Trial
2018
NCT03425552
First Marketed Drug
2021
dimethyl fumarate (tecfidera)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

PHARMATHEN | Pharmathen S.A.

Active Ingredients

Marketed Drugs (1)

dimethyl fumarate (tecfidera) (2021)

Drugs in Phase 2 Trials (1)

paliperidone (invega) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schizophrenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1